<p>Protara Therapeutics（纳斯达克代码：TARA - 获取免费报告）的股票在周六发布给客户和投资者的研究报告中被 Weiss Ratings 的分析师重申了 “卖出（d-）” 评级，Weiss Ratings 报道。</p>
<p>获取 <strong>Protara Therapeutics</strong> 的提醒：</p>
<h2>Protara Therapeutics 价格表现</h2>
<p>周五，TARA 股票交易下跌 0.06 美元，达到 5.10 美元。该公司的交易量为 409,192 股，而其平均交易量为 561,198 股。Protara Therapeutics 的 52 周低点为 1.96 美元，52 周高点为 10.48 美元。该公司的市值为 1.9677 亿美元，市盈率为-3.15，贝塔值为 1.53。该业务的 50 日移动平均线为 4.00 美元，200 日移动平均线为 3.55 美元。</p>
<p>Protara Therapeutics（纳斯达克代码：TARA - 获取免费报告）最后一次发布季度财报是在 8 月 11 日，周一。该公司报告每股收益（EPS）为-0.35 美元，超出分析师一致预期的-0.43 美元，超出幅度为 0.08 美元。研究分析师预计 Protara Therapeutics 在当前年度的每股收益将为-3.32 美元。</p>
<h2>机构投资者对 Protara Therapeutics 的看法</h2>
<p>一些机构投资者最近对 TARA 的持仓进行了调整。新泽西州警察和消防员退休系统在第二季度购买了 Protara Therapeutics 的新股份，价值约 30,000 美元。Quadrature Capital Ltd 在第二季度购买了 Protara Therapeutics 的新股份，价值约 35,000 美元。摩根大通在第二季度购买了 Protara Therapeutics 的新股份，价值约 46,000 美元。洛杉矶资本管理公司在第二季度购买了 Protara Therapeutics 的新股份，价值约 47,000 美元。最后，Intech Investment Management LLC 在第二季度购买了 Protara Therapeutics 的新股份，价值约 49,000 美元。对冲基金和其他机构投资者持有该公司 38.13% 的股票。</p>
<h2>Protara Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Protara Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于推进用于治疗癌症和罕见疾病的变革性疗法。该公司的主导项目是 TARA-002，一种正在进行的细胞治疗，目前处于针对非肌肉侵袭性膀胱癌和淋巴畸形的二期临床试验中。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票比 Protara Therapeutics 更好</li>
<li>什么是财报？</li>
<li>Tractor Supply 股票看起来像是一个买入并持有的赢家</li>
<li>如何使用股票筛选器寻找股票</li>
<li>3 只远低于 52 周高点的股票有望在第四季度反弹</li>
<li>投资优先股与普通股的比较</li>
<li>大银行在财报季节开始时设定基调</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Protara Therapeutics 吗？</h2>
<p>在你考虑 Protara Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Protara Therapeutics 并不在名单上。</p>
<p>虽然 Protara Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

TARA

<p>Weiss Ratings 已重新确认 Protara Therapeutics (NASDAQ:TARA) 的 “卖出 (D-)” 评级。该股票交易价格下跌至 $5.10，52 周范围为 $1.96 至 $10.48。Protara 报告的季度每股收益为 ($0.35)，超过了 ($0.43) 的预期。机构投资者持有该公司 38.13% 的股份，该公司专注于癌症和罕见疾病的治疗，其主要项目正在进行膀胱癌的二期临床试验</p>

<p>Protara Therapeutics (NASDAQ:TARA - Get Free Report)'s stock had its &#34;sell (d-)&#34; rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.</p>
<div class="lb-trans"><p>Protara Therapeutics（纳斯达克代码：TARA - 获取免费报告）的股票在周六发布给客户和投资者的研究报告中被 Weiss Ratings 的分析师重申了 “卖出（d-）” 评级，Weiss Ratings 报道。</p>
</div><p>Get <strong>Protara Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Protara Therapeutics</strong> 的提醒：</p>
</div><h2>Protara Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Protara Therapeutics 价格表现</h2>
</div><p>TARA stock traded down $0.06 during trading on Friday, reaching $5.10. The company had a trading volume of 409,192 shares, compared to its average volume of 561,198. Protara Therapeutics has a 52 week low of $1.96 and a 52 week high of $10.48. The company has a market cap of $196.77 million, a P/E ratio of -3.15 and a beta of 1.53. The business has a 50 day moving average of $4.00 and a 200 day moving average of $3.55.</p>
<div class="lb-trans"><p>周五，TARA 股票交易下跌 0.06 美元，达到 5.10 美元。该公司的交易量为 409,192 股，而其平均交易量为 561,198 股。Protara Therapeutics 的 52 周低点为 1.96 美元，52 周高点为 10.48 美元。该公司的市值为 1.9677 亿美元，市盈率为-3.15，贝塔值为 1.53。该业务的 50 日移动平均线为 4.00 美元，200 日移动平均线为 3.55 美元。</p>
</div><p>Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.08. Research analysts expect that Protara Therapeutics will post -3.32 earnings per share for the current year.</p>
<div class="lb-trans"><p>Protara Therapeutics（纳斯达克代码：TARA - 获取免费报告）最后一次发布季度财报是在 8 月 11 日，周一。该公司报告每股收益（EPS）为-0.35 美元，超出分析师一致预期的-0.43 美元，超出幅度为 0.08 美元。研究分析师预计 Protara Therapeutics 在当前年度的每股收益将为-3.32 美元。</p>
</div><h2>Institutional Investors Weigh In On Protara Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Protara Therapeutics 的看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in TARA. Police &amp; Firemen s Retirement System of New Jersey purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $30,000. Quadrature Capital Ltd purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $35,000. JPMorgan Chase &amp; Co. purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $46,000. Los Angeles Capital Management LLC purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $47,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Protara Therapeutics during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 38.13% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近对 TARA 的持仓进行了调整。新泽西州警察和消防员退休系统在第二季度购买了 Protara Therapeutics 的新股份，价值约 30,000 美元。Quadrature Capital Ltd 在第二季度购买了 Protara Therapeutics 的新股份，价值约 35,000 美元。摩根大通在第二季度购买了 Protara Therapeutics 的新股份，价值约 46,000 美元。洛杉矶资本管理公司在第二季度购买了 Protara Therapeutics 的新股份，价值约 47,000 美元。最后，Intech Investment Management LLC 在第二季度购买了 Protara Therapeutics 的新股份，价值约 49,000 美元。对冲基金和其他机构投资者持有该公司 38.13% 的股票。</p>
</div><h2>Protara Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Protara Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.</p>
<div class="lb-trans"><p>Protara Therapeutics, Inc 是一家临床阶段的生物制药公司，致力于推进用于治疗癌症和罕见疾病的变革性疗法。该公司的主导项目是 TARA-002，一种正在进行的细胞治疗，目前处于针对非肌肉侵袭性膀胱癌和淋巴畸形的二期临床试验中。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Protara Therapeutics</li>
<li>What Are Earnings Reports?</li>
<li>Tractor Supply Stock Looks Like a Buy-and-Hold Winner</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Big Banks Are Setting the Tone as Earnings Season Kicks Off</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Protara Therapeutics 更好</li>
<li>什么是财报？</li>
<li>Tractor Supply 股票看起来像是一个买入并持有的赢家</li>
<li>如何使用股票筛选器寻找股票</li>
<li>3 只远低于 52 周高点的股票有望在第四季度反弹</li>
<li>投资优先股与普通股的比较</li>
<li>大银行在财报季节开始时设定基调</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TARA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Protara Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Protara Therapeutics 吗？</h2>
</div><p>Before you consider Protara Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Protara Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Protara Therapeutics 并不在名单上。</p>
</div><p>While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Protara Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Protara Therapeutics（纳斯达克股票代码：TARA）在 Weiss Ratings 被评为卖出（D-）评级